Ezetimibe Therapy: Comprehensive Clinical Guide
Ezetimibe 10 mg once daily is the standard dose for all indications, taken with or without food, and requires no routine monitoring in most patients. 1
Dosing Guidelines
Standard Dosing
- 10 mg orally once daily - this is the only FDA-approved dose for all indications 1
- Can be taken with or without food
- No dose adjustment needed for:
- Age (including elderly ≥75 years)
- Sex
- Race
- Mild hepatic impairment
- Mild-to-severe renal insufficiency 2
Special Timing Considerations
When combined with bile acid sequestrants (cholestyramine, colestipol): Administer ezetimibe either ≥2 hours before OR ≥4 hours after the bile acid sequestrant to avoid significantly reduced absorption 1
Cyclosporine Co-administration
Start at 5 mg daily (half the standard dose) when used with cyclosporine, then titrate upward based on response 3. The drug interaction increases ezetimibe exposure 2.3- to 12-fold, which can produce supratherapeutic LDL-C reductions 3.
Clinical Indications (FDA-Approved)
Primary Hyperlipidemia
- Combination with statin (preferred) or alone when additional LDL-C lowering is needed 1
- Adults and pediatric patients ≥10 years with heterozygous familial hypercholesterolemia (HeFH)
Homozygous Familial Hypercholesterolemia (HoFH)
- In combination with statin and other LDL-C lowering therapies
- Adults and pediatric patients ≥10 years 1
Mixed Hyperlipidemia
- In combination with fenofibrate 1
Homozygous Familial Sitosterolemia
- Adults and pediatric patients ≥9 years 1
When to Add Ezetimibe: Risk-Stratified Algorithm
Very High-Risk Patients (Secondary Prevention/ASCVD)
Add ezetimibe when LDL-C remains ≥70 mg/dL (1.8 mmol/L) on maximally tolerated statin 4, 5
- For acute coronary syndrome: Start high-intensity statin PLUS ezetimibe immediately (not sequential) 6
- If LDL-C remains ≥100 mg/dL (2.6 mmol/L) on statin + ezetimibe, add PCSK9 inhibitor 4
High-Risk Patients (Primary Prevention)
Add ezetimibe when LDL-C goals not achieved on maximum tolerated statin dose 4
- European guidelines: LDL-C goal <70 mg/dL (1.8 mmol/L) 4
- If non-HDL-C reduction <40% from baseline after 3 months on maximum statin, add ezetimibe 4
Statin-Intolerant Patients
Ezetimibe monotherapy is appropriate when statins cannot be tolerated 5, 1
- Particularly effective in patients ≥75 years for primary prevention 7
- The EWTOPIA 75 trial demonstrated ASCVD event reduction with ezetimibe alone in elderly patients 7
Expected LDL-C Reduction
- Monotherapy: 17-20% reduction 5, 8
- Added to statin: Additional 15-25% reduction 5, 9
- Combination with bempedoic acid: 38% reduction (placebo-corrected) 5
Assess LDL-C as early as 4 weeks after initiating therapy 1
Monitoring Requirements
Routine Monitoring
No routine laboratory monitoring is required for ezetimibe monotherapy 1
When Combined with Statins
- Monitor liver enzymes according to the statin's prescribing information 1
- Perform liver enzyme testing as clinically indicated
- Consider withdrawing ezetimibe if ALT or AST ≥3× ULN persist 1
Cyclosporine Co-administration
Monitor cyclosporine levels closely when initiating or adjusting ezetimibe, as both drugs' exposures increase 1, 3
Contraindications
Absolute Contraindications
- Hypersensitivity to ezetimibe or any excipient 1
- When used with a statin, fenofibrate, or other LDL-C lowering therapy: contraindicated if that agent is contraindicated in the patient 1
Relative Contraindications/Cautions
- Not recommended in moderate-to-severe hepatic impairment 5
- Pregnancy: Avoid use; no safety data in humans 5
- Lactation: Avoid use 5
Drug Interactions
Significant Interactions Requiring Action
Cyclosporine 1
- Increases ezetimibe exposure 2.3- to 12-fold
- Increases cyclosporine exposure
- Action: Start ezetimibe at 5 mg daily; monitor cyclosporine levels closely
Bile Acid Sequestrants (cholestyramine, colestipol) 1, 2
- Significantly decrease ezetimibe bioavailability
- Action: Separate administration by ≥2 hours before or ≥4 hours after sequestrant
Fibrates (other than fenofibrate) 1
- Coadministration not recommended until adequately studied
- Action: Avoid combination; use fenofibrate if fibrate needed
Fenofibrate 1
- Increases ezetimibe exposure but generally well-tolerated
- Action: Monitor for cholelithiasis; obtain gallbladder studies if suspected
Simvastatin/Pravastatin with Bempedoic Acid 5
- When using ezetimibe + bempedoic acid combination
- Action: Avoid simvastatin >20 mg daily or pravastatin >40 mg daily
No Clinically Significant Interactions
The following can be used without dose adjustment 2:
- Atorvastatin, fluvastatin, lovastatin, rosuvastatin (most statins)
- Digoxin
- Warfarin
- Oral contraceptives
- Glipizide
- Cimetidine
- Antacids
- Food
Adverse Effects
Common (≥2% incidence)
Ezetimibe Monotherapy 1
- Upper respiratory tract infection
- Diarrhea
- Arthralgia
- Sinusitis
- Pain in extremity
- Fatigue
- Influenza
Ezetimibe + Statin 1
- Nasopharyngitis
- Myalgia
- Upper respiratory tract infection
- Arthralgia
- Diarrhea
- Back pain
Serious Adverse Effects
Myopathy and Rhabdomyolysis 1
- Can occur with ezetimibe alone but more common with statin combination
- Most post-marketing cases involved concomitant statin or fibrate use
- Action: Discontinue ezetimibe if myopathy suspected
Liver Enzyme Elevations 1
- Increases in transaminases reported
- More common with statin combination
- Action: Monitor as clinically indicated; withdraw if ALT/AST ≥3× ULN persist
Alternative Options
When Ezetimibe Insufficient or Not Tolerated
PCSK9 Inhibitors (alirocumab, evolocumab) 4, 5
- Add when LDL-C remains ≥100 mg/dL (2.6 mmol/L) on statin + ezetimibe in very high-risk patients
- Subcutaneous injection every 2-4 weeks
- 50-60% additional LDL-C reduction
- Proven cardiovascular outcomes benefit
Bempedoic Acid 5
- Oral alternative; 180 mg daily
- 17-18% LDL-C reduction when added to statin
- Available as fixed-dose combination with ezetimibe (38% reduction)
- Useful in statin-intolerant patients
- Caution: Monitor for hyperuricemia and tendon disorders
Inclisiran 4
- siRNA therapy targeting PCSK9
- Subcutaneous injection every 6 months after loading doses
- Similar efficacy to PCSK9 monoclonal antibodies
- Better adherence due to infrequent dosing
Emerging Strategy: Moderate-Intensity Statin + Ezetimibe as Initial Therapy
Consider starting moderate-intensity statin + ezetimibe together rather than high-intensity statin alone 10
- Better adherence and tolerability than statin intensification
- Achieves similar LDL-C reductions
- Recommended as primary strategy in 2023 Chinese Guidelines 10
- Particularly useful in patients hesitant about high-intensity statins
Clinical Pearls and Pitfalls
Key Advantages of Ezetimibe
- Excellent safety profile - similar to placebo in most studies 8
- No CYP450 metabolism - minimal drug interaction potential 2, 8
- Once-daily dosing with high adherence
- Generic availability - cost-effective 5
- Proven cardiovascular outcomes in IMPROVE-IT and SHARP trials 5
Common Pitfalls to Avoid
- Forgetting bile acid sequestrant timing - leads to treatment failure due to reduced absorption
- Using standard 10 mg dose with cyclosporine - causes excessive LDL-C lowering
- Sequential rather than immediate combination therapy in ACS - delays LDL-C goal attainment 6
- Combining with non-fenofibrate fibrates - inadequately studied safety profile
- Overlooking ezetimibe monotherapy in elderly - particularly effective in patients ≥75 years 7
Special Population Considerations
Elderly (≥75 years): Ezetimibe monotherapy is particularly effective due to increased cholesterol absorption efficiency with age 7
Chronic kidney disease: No dose adjustment needed; proven benefit in SHARP trial 5